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Purpose: The objective of this study was to assess the initial and 1-year outcome of endovascular treatment of thoracic
aortic aneurysms and dissections collated in the European Collaborators on Stent Graft Techniques for Thoracic Aortic
Aneurysm and Dissection Repair (EUROSTAR) and the United Kingdom Thoracic Endograft registries.
Methods: Four hundred forty-three patients underwent endovascular repair of thoracic aortic disease between September
1997 and August 2003 (EUROSTAR, 340 patients; UK, 103 patients). Patients represented 4 major disease groups:
degenerative aneurysm (n 249), aortic dissection (n 131), false anastomotic aneurysm (n 13), and traumatic aortic
injury (n  50).
Results: Mean age in the entire study group was 63 years. Fifty-two percent of patients were deemed at high risk for open
surgery because of major comorbidity. Sixty percent of patients underwent an elective procedure, and 35% required
emergency treatment. Conventional indications for treatment of aortic dissection, including aortic expansion, continuous
pain, rupture, or symptoms of branch occlusion constituted the basis for endograft placement in 57% of patients, whereas
in 43% of patients aortic dissections were asymptomatic. Primary technical success was obtained in 87% of patients with
degenerative aneurysm and in 89% with aortic dissection. Paraplegia was a postoperative complication in 4.0% of patients
with degenerative aneurysm and 0.8% of patients with aortic dissection (not significant). Thirty-day mortality in the
entire study group was 9.3%, with mortality rates after elective procedures of 5.3% for degenerative aneurysms and 6.5%
for aortic dissection. Mortality for degenerative aneurysm after emergency repair was higher (28%; P <.0001) then after
elective procedures. For aortic dissection the emergency repair rate was 12% (not significant compared with elective repair
of aortic dissection, and P  .025 compared with emergency repair of degenerative aneurysm). One-year follow-up was
complete in 195 patients. The outcome at 1 year was more favorable for aortic dissection than for degenerative aneurysm
with regard to aortic expansion (0% vs 15%; P  .001) and late survival (90% vs 80%; P  .048). In the groups with false
anastomotic aneurysm and traumatic aortic injury, 30-day mortality rates were 8% and 6%, respectively.
Conclusion: This multicenter experience demonstrates acceptable rates for operative mortality and paraplegia after
endovascular repair of thoracic aortic disease. Outcome after 30 days and 1 year was more favorable for aortic dissection
than for degenerative aneurysm. However, the durability of this technique is currently unknown, and continued use of
registries should provide data from long-term follow-up. (J Vasc Surg 2004;40:670-80.)Elective endovascular treatment of thoracic aortic dis-
ease has been used to treat degenerative aneurysms, false
aneurysms, infected aneurysms, and chronic dissections.
Emergency indications for stent-graft treatment include
ruptured aneurysms, traumatic aortic injuries, acute type B
aortic dissections, and intramural hematomas. The mortal-
ity rate associated with open surgery is considerable, and
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doi:10.1016/j.jvs.2004.07.008670ranges from 5% to 20% in thoracic aortic aneurysm (TAA)
disease and from 6% to 67% in type B aortic dissection.1-9
The advent of endovascular technology offers a minimally
invasive alternative treatment for thoracic aortic disease.
Several small series have reported encouraging early results
with this technique.1,10-16 We report the combined expe-
rience from 2 voluntary multicenter registries involved with
data recording and evaluation of endovascular repair of
thoracic aneurysms and dissection. The first was organized
by the European Collaborators on Stent Graft Techniques
for Thoracic Aortic Aneurysm and Dissection Repair
(EUROSTAR), and the second by the United Kingdom
Thoracic Endograft Registry. The objective was to assess
early and 1-year results in a large patient series to obtain
insight about endovascular repair of thoracic aortic disease
in Europe.
METHODS
A total of 443 patients with aneurysm or dissection in the
thoracic aorta who underwent endovascular repair during the
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basis of this analysis. Ten patients with thoracic aortic abnor-
malities classified as penetrating ulcers were excluded from the
assessment, because this number was considered too small for
meaningful conclusions. Thirty-seven patients who received
treatment between August 1997 and January 2000 were
entered retrospectively into the EUROSTAR database. From
January 2000 data were entered prospectively on an intent-to-
treat basis into EUROSTAR (340 patients) and the UK
Thoracic Endograft Registry (103 patients). All patients who
survived the operation period underwent minimal follow-up
of 1 month (range, 1-60 months).
Patients were recruited from 62 European institutions
(see Appendix). Centers participated in only 1 of the 2
registries. Patients received the following commercially
available, Communaute´ Europe´enne (CE)–approved de-
vices: Talent (Medtronic/AVE), Excluder (W. L. Gore &
Associates), Zenith (William Cook Europe), or Endofit
(Endomed).17 Patients were categorized into 4 groups:
degenerative TAA, aortic dissection, false anastomotic an-
eurysm, and traumatic rupture of the thoracic aorta. Emer-
gency procedures were defined arbitrarily as those that
required treatment within 7 days of first presentation. Col-
lected baseline data included information about comorbid-
ity, fitness for open surgery (classification according to the
American Society of Anesthesiologists [ASA]), aneurysm
anatomy, and operative details. The information was re-
corded by the participating institutions on case record
forms, and was submitted for inclusion to either the United
Kingdom or continental European data registry center.18
Findings at follow-up visits, which involved clinical exami-
nation, computed tomography (CT), angiography, mag-
netic resonance imaging, or thoracic or transesophageal
echocardiography were recorded on data forms and re-
turned at regular intervals to the data registry centers for
processing and analysis. There was no outside monitoring
of the centers, nor involvement of a core laboratory for
evaluation of CT scans or other imaging studies. Early
complications included intraoperative device-related prob-
lems, including inability to advance the delivery system,
inability to deploy the device, stent-graft migration, occlu-
sion, and stenosis; arterial injuries; postoperative systemic
complications, including cardiac, pulmonary, and renal
function impairment; and neurological complications. Pri-
mary technical success was defined as complete exclusion of
the aneurysm or coverage of the proximal entry tear in
aortic dissection, survival of the patient, and absence of a
primary endoleak. Patients were followed up at 1, 6, and 12
months, and annually thereafter. Satisfactory findings at CT
were defined by absence of endoleak, stent-graft migration,
kinking, stenosis, thrombosis, and aneurysm expansion. In
case of dissection additional criteria included complete
thrombosis of the false lumen and, in extensive dissection,
thrombosis of the proximal segment of the dissection (par-
tial thrombosis). Reminders for overdue follow-up data
were regularly sent to the institutions participating in the
project.Outcome reporting adhered to the guidelines from the
ad hoc Committee for Standardized Reporting Practises in
Vascular Surgery of the Society for Vascular Surgery/
American Association for Vascular Surgery.18 Data were
presented as means and ranges. Missing data were indicated
as such in this overview. Death occurring within 30 days of
the initial procedure was categorized as operative death,
and deaths occurring after 30 days as late deaths. Other
outcome events observed during follow-up included en-
doleak, graft migration, device disintegration, and contin-
ued aneurysm expansion. Statistical significance of differ-
ences in proportions was determined with 2 tests. The
Kaplan-Meier method was used to determine cumulative
survival. The data were analyzed with SAS statistical soft-
ware, version 8.0 (SAS Institute).
RESULTS
The entire study cohort consisted of 443 patients, of
whom 331 (75%) were male and 112 (25%) were female.
Mean patient age at operation was 63 years (range,
13-89 years). Degenerative aneurysm was present in 249
patients, aortic dissection in 131 patients, false anasto-
motic aneurysm in 13 patients, and traumatic aortic
injury in 50 patients. Comorbid factors were frequently
present in all groups. In the entire cohort previous
cardiothoracic surgery had been performed in 7.2% of
patients, a previous myocardial infarction had occurred
in 17% of patients, and chronic obstructive pulmonary
disease was observed in 21% of patients. Moreover, 52%
of patients had preoperative ASA class 3 or 4 disease
(Table I). The main differences between the 4 patient
categories were a higher prevalence of female patients in
the false anastomotic aneurysm group (61%; P  .002),
older age in the degenerative aneurysm group (mean, 71
years; P  .0001), higher prevalence of smokers in the
degenerative aneurysm group (44%; P  .0001), and
lower prevalence of previous cardiac events (myocardial
infarction, angina, congestive heart failure) in the false
anastomotic aneurysm group (7.7%; P  .036) and the
traumatic aortic injury group (6.0%; P  .0001). In
addition, a higher prevalence of previous cardiac thoracic
surgery in the false anastomotic aneurysm group was
observed (69%; P  .0001).
Ten percent to 14% of patients in most subgroups had
involvement of the aortic arch or the ascending thoracic
aorta. In contrast, in the false anastomotic aneurysm group
the arch was involved in 38% of patients (Table II). One or
more segments of the descending thoracic aorta were af-
fected in 77% to 93% of patients with aneurysmal lesions
and in 100% of patients with aortic dissection. The maxi-
mum diameter was largest (66 mm) in patients with degen-
erative aneurysm compared with the other groups. Degen-
erative aneurysm and false anastomotic aneurysm were
most frequently treated electively (69% and 62%, respec-
tively), whereas, and understandable, most patients with
traumatic aortic injury required emergency treatment 54%;
(Fig). In patients with aortic dissection equal proportions
bstruc
tid or
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46%, respectively).
A more favorable outcome after endovascular repair
of aortic dissection compared with degenerative aneu-
rysm included lower 30-day mortality for emergency
repair (P  .025), no late aortic expansion (P  .001),
Table I. Patient demographic data
Patients (N  443)
Degenerative
aneurysm
n %
249 56.2
Sex
Male 185 74.3 1
Female 64 25.7
Age (y) (range) 71.25 (34–89)
ASA 3 145 58.2
Smoker 110 44.2
Pregips cardiac intervention 22 8.8
Previous cardiothoracic surgery 11 4.4
History of MI 55 22.1
History of angina 40 16.1
History of CHF 15 6
History of COPD 70 28.1
MI, Myocardial infarction; CHF, congestive heart failure; COPD, chronic o
Table II. Anatomic and procedural details
Patients (N  443)
Atherosclerotic
aneurysm
(n  249)
n %
Localization of thoracic aortic disease*
Ascending —
Aortic arch 26 13.9†
Descending TAA 173 92.5†
Proximal third 97 51.9†
Middle third 94 50.3†
Distal third 70 37.4†
Maximum diameter, TAA (range) 66.3 (30–116)
Minimum diameter, true lumen (range) NA
Regional or local anesthesia 38 15.2
Access to disease
Femoral artery 195 78.3
Iliac artery 28 11.2
Abdominal artery 13 5.2
Number of stents used

1 85 34.1
2 91 36.5
3 64 25.7
Additional procedures
Endovascular¶ 58 23.3
Surgical# 66 26.4
TAA, Thoracic aortic aneurysm.
*Multiple sites per patients possible.
†Data for 62 patients missing. Percentages calculated on the basis of 187 pa
‡Data for 31 patients missing. Percentages calculated on the basis of 100 pa
Data for 11 patients missing.
¶Included stents in iliac or abdominal aorta, balloon fenestration of dissecti
#Included open surgery of thoracic or abdominal aorta and subclavian caroand higher 1-year survival (P  .048). In addition,
trends were observed for lower rates of postoperative
paraplegia and 1-year aneurysm-related death (Tables III
and IV).
Degenerative aneurysms. Of the 249 patients with
degenerative aneurysm, three fourths were male (Table I).
Aortic
dissection
False anastomotic
aneurysm
Traumatic
rupture
% n % n %
29.6 13 2.9 50 11.3
77.1 5 38.5 40 80
22.9 8 61.5 10 20
(18–86) 46.1 (30–78) 46 (13–76)
42.0 6 46.1 24 48
19.8 4 30.8 12 24
7.6 1 7.7 1 2
9.2 9 69.2
13.7 1 7.7 1 2
8.4 1 2
9.2 1 2
13.0 1 7.7 5 10
tive pulmonary disease.
Aortic
dissection
(n  131)
False anastomotic
aneurysm
(n  13)
Traumatic
rupture
(n  50)
n % n % n %
3 2.3 1 7.7 —
13 9.9 5 38.5 6 12.0
31 100.0 10 76.9 43 86.0
63 63.0‡ 7 53.5 41 82.0
28 28.0‡ — 1 2.0
14 14.0‡ 3 23.5 1 2.0
45.8 (42–100) 57 (40–85) 54.5 (30–80)
14.9 (10–40) NA NA
14 10.7 1 7.7 2 4.0
09 83.2 11 84.6 42 84.0
5 3.8 1 7.7 8 16.0
3 2.3 1 7.7 —
83 63.4 11 84.6 40 80.0
35 26.7 2 1.4 8 16.0
13 9.9 — —
8 6.1 — 1 2.0
39 29.7 4 30.8 15 30.0
.
.
p, and coiling of endoleak.
innominate artery transposition or bypass.n
131
01
30
61.5
55
26
10
12
18
11
12
171
1
tients
tients
on fla
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gency repair (Fig). More than half (58%) of the patients in
this group were classified as at high risk (ASA class 3 or 4)
and would not have been considered candidates for open
surgical TAA repair. The degenerative aneurysm was lo-
cated in the aortic arch in 14% of patients, with an approx-
imately even distribution in the proximal, middle, and distal
descending thoracic aorta (Table II). The configuration of
the aneurysm was fusiform in 64%, saccular in 32%, and not
recorded in 4.4%. To obtain an adequate proximal landing
zone it was necessary to place a stent graft over the origin of
the left subclavian artery in 42 patients (17%). Of these, 22
patients had preemptive revascularization with subclavian
artery transposition or bypass. Of the total of 66 adjunctive
surgical procedures, 14 were performed in the abdominal
aorta and 2 in the thoracic aorta.
Primary technical success was achieved in 87% (Table V).
Device-related complications occurred intraoperatively in 16%
of patients, and arterial injuries in 2.4% of patients. Neurologic
events in most cases (59%) consisted of paraplegia or parapa-
resis. Postoperative systemic problems included cardiac, pul-
monary, and renal function impairment, and occurred in
approximately one fourth of patients. Thirty-day mortality
rate in the entire group with degenerative aneurysm was 10%.
However, in patients who underwent an emergency proce-
dure the mortality rate was 28%, and in those who underwent
elective repair was 5.3% (P .0001; Table III). One year after
operation 80% of patients with available follow-up data had
satisfactory findings at CT examination (Table IV). Expansion
of the aneurysm was the most frequent adverse event, occur-
ring in 14.5% of patients. The mortality rate between 1 and 12
months was 10%. In 2.1%, death was aneurysm-related. Late
aneurysm rupture occurred in 1 patient. The overall cumula-
tive survival rate in this subgroup was 80% after 12 months.
Distribution of various thoracic aortic diseases treated with elective
and emergency procedures. DA, Degenerative aneurysm; DI, aor-
tic dissection; FA, false anastomotic aneurysm; TA, traumatic
aortic injury.Aortic dissection. Patients with aortic dissection were
on average 10 years younger than those with degenerative
aneurysm. Forty-two percent of these patients had an ASA
classification of 3 or greater (Table I). Dissections were type
A in 7 patients (5.3%), and type B in 106 patients (81%). In
18 patients (14%), classification was not available. The
dissection was located in the descending aorta in all pa-
tients. In addition, dissection was present in the ascending
aorta in 2.3% of patients, and in the aortic arch in 10% of
patients (Table II). At the time of the procedure 43% of
patients had no symptoms, and 57% had symptoms of
rupture, aortic expansion, or side branch occlusion. Elec-
tive and emergency repair in this group was performed in
similar proportions of patients (Fig). Emergency proce-
dures were associated with acute symptoms in almost all
patients (Table VI). In elective procedures symptoms were
present in 74% of patients. The severity of the dissection
was characterized by the following findings: the dissection
extended down to the descending aorta in 27% of patients,
to the celiac trunk in 20% of patients, to the abdominal
aortic bifurcation in 17% of patients, and into the iliac
arteries in 22% of patients. The proximal extension of the
aortic dissection reached to the left subclavian artery in 39%
of patients, into the aortic arch in 9.2% of patients, to the
ascending aorta in 7.6% of patients, and to the aortic valve
in 0.8% of patients. The minimum diameter of the true
lumen was 15 mm, and the maximum diameter of the
overall aorta was 46 mm. The endograft procedure with
aortic dissection did not involve any stent-graft placement
in the ascending aorta. Additional supra-aortic vessel revas-
cularization was performed in 15 patients (12%), and ab-
dominal aortic procedures in 2 patients (1.5%). Subclavian
artery overstenting was performed in 37 patients, of whom
subclavian artery revascularization was performed in 15
patients. Of these operations, 1 was performed as a second-
ary procedure, because of symptoms.
In 89% of patients primary technical success was achieved;
the remaining 11% had either incomplete covering of the
entry tear, persistent flow without thrombosis of the largest
portion of the false lumen, no expansion of the true lumen, or
endoleaks (Table V). This success rate was 86% in the elective
group versus 95% in the emergency group. The true lumen
expanded from 15 mm to 26 mm. Neurologic complications
consisted of paraplegia in 1 patient who initially underwent
emergency repair, and stroke in 2 patients who underwent
elective procedures. Systemic postoperative problems oc-
curred in one third of patients. The overall 30-day mortality
rate was 8.4%. Patients who underwent an emergency proce-
dure had an early mortality rate of 12%, versus 6.5% in elective
cases (P  .55; Table III). One year after operation 94% of
patients followed up during this interval had satisfactory find-
ings at CT examination (Table IV). New endoleaks were
observed in 2.8% of patients. Late death occurred in 1.5% of
patients, and the cumulative survival rate after 1 year was 90%
in patients with aortic dissection.
False anastomotic aneurysm. In contrast with the
other subgroups, the proportion of female patients (61%) was
significantly greater than male patients (39%) (P .006). This
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years). Forty-six percent of this group was considered
unfit for open operation because of the aneurysms, and
69% had undergone previous cardiothoracic surgery (Ta-
ble I). Two thirds of these patients were operated on
electively, and one third required emergency repair
(Fig). The false anastomotic aneurysm was located in the
ascending aorta in 1 patient (7.7%), in the aortic arch in
39% of patients, and in the descending aorta in 77% of
patients (Table II). In the patient with involvement of
the ascending aorta a stent graft was placed in that
segment.
During the operation, device-related complications oc-
curred in 46% of patients (Table V). However, most com-
plications were overcome, and technical success was 92%.
After treatment, neurologic complications occurred in 1 of
13 patients (7.7%). Systemic complications were observed
in 15% of patients. Early death in patients with false anas-
tomotic aneurysm occurred in 1 patient (7.7%). This pa-
tient was 1 of 5 who underwent an emergency procedure
(Table III). One year after operation 88% of patients had
satisfactory CT findings (Table IV). Enlargement of the
aneurysm developed in 13% of patients. No late deaths,
Table III. Thirty-day mortality in elective vs emergency p
Degenerative
aneurysm
(n  249)
Aor
(
n % n
Type of procedure
Elective 171 62
Emergency 61 60
Not reported 17 9
30-Day mortality
Elective 9 5.3* 4
Emergency 17 27.9* 7
Not reported — —
*Percentages calculated by dividing numbers of deaths by total number of
Table IV. One-year outcome
Degenerative
aneurysm
(n  96)
n %
Satisfactory findings at CT 77 80.2 6
Endoleak 4 4.2
Migration —
Expansion aneurysm 14 14.6
Late intervention 5 5.2
Late rupture 1 1
TAA related death 2 2.1
Unrelated death 8 8.3
Cumulative survival rate 80.3
TAA, Thoracic aortic aneurysm.conversions, or ruptures were reported. The cumulative
survival rate at 12 months in this group was 92%.
Traumatic rupture of thoracic aorta. The average
patient age in this group was 46 years, which was lower than
in the other subgroups (P  .0001; Table I). Of no
surprise, most patients (55%) in this group required emer-
gency treatment (Fig). traumatic aortic injury was located
in most patients (82%) in the proximal descending aorta
(Table II).
The primary technical success rate in this category was
96%. Intraoperatively, device-related complications and arte-
rial injuries both were observed in 12% of patients (Table V).
After treatment, neurologic complications occurred in 6.0% of
patients. In 32% of this category systemic problems were
reported. Three patients (6.0%) died within 30 days after
operation. All 3 were among the 27 patients who required an
emergency procedure. No patient with delayed or elective
endograft treatment of traumatic aneurysm died early (Table
III). One year after operation 83% of patients had satisfactory
findings at CT examination (Table IV). Late death occurred
in 13% of patients. However, no late ruptures or conversions
were documented. The cumulative survival rate at 1 year in
this group was 82%.
dures
ssection
31)
False anastomotic
aneurysm
(n  13)
Traumatic
rupture
(n  50)
% n % n %
8 22
5 27
— 1
6.5* — —
11.7* 1 20.0* 3 11.1
— —
ts per type of procedure.
c dissection
 67)
False
anastomotic
aneurysm
(n  8)
Traumatic
rupture
(n  24)
% n % n %
94.0 7 87.5 20 83.3
1.5 — —
— — —
— 1 12.5 2 8.3
1.5 — —
— — —
— — —
1.5 — 3 12.5
90.2 92.3 82.3roce
tic di
n  1
patienAorti
(n
n
3
1
1
1
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A lower incidence of TAA in comparison with ab-
dominal aortic aneurysm has resulted in slower develop-
ment and less widespread experience with endovascular
procedures to treat TAA. Stent-graft repair of thoracic
aortic disease is an appealing alternative to open surgery,
because it avoids thoracotomy, aortic cross-clamping,
and left-sided heart bypass. The descending thoracic
aorta is suitable for this minimally invasive approach
because, although it may be elongated and tortuous in
patients with aneurysm, it usually enables good adapta-
tion of endografts. Operation time and hospital stay are
significantly shorter compared with those with open
surgery.19 The application rate of stent-graft repair in 1
series on various pathologic conditions of the descend-
ing thoracic aorta was as high as 57%.15 In the present
analysis patients were categorized into 4 categories ac-
cordingly to type of aortic disease, that is, degenerative
aneurysm, aortic dissection, false anastomotic aneurysm,
and traumatic aortic injury. A high prevalence of comor-
bid factors was noted, and a large proportion of patients
Table V. Early (30-day) outcome
Atherosclerotic
aneurysm
(n  249)
n %
Technical success 217 87.
Intraoperative complications
Device-related 39 15.
Arterial 6 2.
Complications from operation to discharge
Neurologic 17 6.
Paraplegia or paresis 10 4.
Stroke 7 2.
Systemic 72 28.
Endoleak
Proximal 12 4.
Midgraft 4 1.
Distal 3 1.
Perfusion from side branches 4 1.
30-Day mortality 26 10.
*Vocal cord dysfunction.
†In 2 patients the kind of neurologic complication could not be retrieved.
Table VI. Presence and type of preoperative symptoms in
treat dissection of thoracic aorta
n
No symptoms 20
Persisting back pain/expansion aneurysm/
rupture of thoracic aorta
41
Symptoms of sidebranch occlusion* 5
*Includes paraparesis, paraplegia, intestinal ischemia, renal insufficiency, lim(52%) were classified at ASA greater than 3 and would
thus not be suitable candidates for open thoracic aortic
repair. The population with degenerative aneurysm were
relatively older (mean, 71 years) in comparison with
series on open descending TAA repair (range, 47-65
years).20,21 The possibility to use this technique in frailer
and older patients may increase the applicability of TAA
treatment significantly. Given the higher prevalence of
patients at poor risk, the perioperative mortality rate in
the present overview of 8% in the aortic dissection group
and 10% in the degenerative aneurysm group is accept-
able and in agreement with the previously reported
mortality rate with endografts, which ranged from 3.5%
to 12.5%.6,7,10,15,22 Because of incomparability of pa-
tients, these early mortality rates cannot simply be com-
pared with the results of open surgery. Surgical mortality
rates ranging from 8% to 26% have been reported.6,20,21
When stent-graft attachment is required in the proxim-
ity of the left subclavian artery it is acceptable to overstent
the origin of this vessel to extend the length of neck
available for fixation and seal. Opinions diverge about the
Aortic dissection
(n  131)
False
anastomotic
aneurysm
(n  13)
Traumatic
rupture
(n  50)
n % n % n %
116 88.6 12 92.3 48 96.0
3 2.3 6 45.1 6 12.0
1 0.8 — 6 12.0
3 2.3 1 7.7* 3 6.0†
1 0.8 — —
2 1.5 — 1 2.0
46 35.1 2 15.4 16 32.0
2 1.5 1 7.7 —
2 1.5 — —
2 1.5 — —
2 1.5 — —
11 8.4 1 7.7 3 6.0
ents undergoing elective or emergency procedures to
ctive procedure
(n  62)
Emergency procedure
(n  60)
% n %
32.3 1 1.7
66.1 57 95.0
8.1 17 28.3
emia.1
7
4
8
0
8
8
8
6
2
6
4pati
Ele
b isch
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artery under these circumstances. Overstenting has the
potential for complications, including possible retrograde
endoleak via the subclavian artery, left arm ischemia, and
posterior cerebral stroke, and may increase the risk for
paraplegia. Although these events are infrequent, several
investigators favor routine left subclavian artery revascular-
ization from the common carotid artery.11,16,22,23 In the
degenerative aneurysm and aortic dissection groups in the
present series, subclavian artery overstenting was required
in 17% and 28%, respectively, and additional revasculariza-
tion procedures were performed in almost half of these
patients.
The technical success rate in endovascular procedures
performed to treat degenerative aneurysm was 87%. In
elective degenerative aneurysm the 30-day mortality was
5%, which is lower then the previously reported rate of
12.5% with endografting.10 Successful endovascular man-
agement of acute thoracic rupture was first reported by
Semba et al,24 who observed perioperative death in 2 of 11
patients. In emergency repair in the present atherosclerotic
aneurysm group the 30-day mortality rate was 29%, com-
parable with the results of Semba et al24 and with the 33%
reported by Greenberg et al.10 The incidence of spinal cord
ischemia and paraplegia has been consistently low after
endovascular repair of thoracic aneurysms, even in patients
in whom long aortic segments and the “danger zone”
(T9-L1) that usually gives origin to the anterior spinal
artery had been covered by the endograft. It was noted that
the risk for paraplegia in the degenerative aneurysm group
was highest (4%), whereas in 66% of patients 2 or more
stent grafts were used, indicating long covered aortic seg-
ments. In the aortic dissection group the rate of paraplegia
was significantly lower (0.8%), and multiple endografts
were used in only 37%. However, more factors than the
covered aortic length may determine the risk for spinal cord
ischemia. In comparison, the risk for spinal complications
reported in the endograft literature ranges from 0% to
12%.10,22,25 Avoidance of clamping of the proximal aorta
and prolonged episodes of hypotension may account for
the low incidence of spinal problems. The overall incidence
of stroke was 3%, with manipulation with the introducer
device and guide wire across the aortic arch in proximity of
the orifices of the carotid arteries as known risk factors.
Endoleak after stent-graft treatment of descending TAAs
was relatively infrequent, and was usually graft fixation–
related type I. Type II endoleaks were relatively uncommon
in the present overview, which is in concordance with the
literature.7 Late migration of the endoprothesis occurs,
according to the literature, with an incidence of 0% to 30%.
The higher rates are typically associated with use of early
designs of thoracic endografts and multiple overlapping of
“thromboned” endografts.7,22,26 Because device migra-
tion was not reported during the relatively short follow-up
of 1 year in the present study, proper correlation with the
use of single or multiple endografts was not possible. A
1-year survival rate of 80% in the degenerative aneurysmgroup was observed, which was comparable with the rate of
82% recently reported by Demers et al.27
Reports of successful closure of the entry tear of a dissec-
tion by a stent graft were first published in the late 1990s, and
raised optimism for improvement of both early and late pa-
tient survival. The principle of stent-graft repair in dissection is
based on redirection of flow from the false lumen and recon-
struction of the true lumen when it is collapsed. The goal is to
cause thrombosis of the false lumen, which is assumed to lead
to a healing process of the aortic wall and decreased risk for late
aortic enlargement.28 The indications for stent-graft treat-
ment of type B dissection include, in the first place, symptoms
from progression of the dissection, such as enlargement of the
aortic diameter, ongoing pain despite adequate hypotension,
branch involvement resulting in end-organ ischemia (visceral,
renal, lower extremity, spinal cord), or rupture.29-31 A second
indication category consists of patients with few or no symp-
toms after the initial phase. In these patients stent grafting may
be used in an attempt to prevent late aneurysm formation,
which occurs in 30% to 40% of patients who receive conserva-
tive management.32 At this time there is no firm evidence that
endografting will reduce late sequelae of dissection. A clinical
trial is in progress to assess whether this category indeed will
benefit from remodeling of the aorta and reduced risk for late
complications.32,33 The indications followed by the partici-
pants in this registry included both asymptomatic (43%) and
symptomatic (57%) disease.
Use of endografts in aortic dissection differs from that
in degenerative aneurysm in that the expanding stent may
perforate the dissecting flap, causing reentry of flow, en-
abling the false lumen distal from the stent graft to remain
patent. No or incomplete thrombosis of the false lumen was
observed in 14% of patients with aortic dissection in this
study, which is in concordance with previous institutional
observations.34 As a consequence, stent-graft technique in
dissection must include use of flexible devices, with no bare
stents at the extremities, to avert damage to the vulnerable
aortic wall or dissecting septum, and minimal oversizing or
ballooning of the stent graft.35,36
In 89% of patients with aortic dissection treated with an
endovascular technique the procedure was performed suc-
cessfully. The 30-day mortality rate of 6.5% in elective
dissections is comparable with the rate of 7% reported by
Shim et al.37 This rate is lower than with open surgery to
treat type B dissection, which may be associated with a
mortality rate as high as 67%.20,29,37-44 Again, direct com-
parison may not be justified, because of differences in
patient selection. The 30-day mortality rate in the emer-
gently treated dissection group was 12%, comparable with
the previously reported mortality rate of 16% with endovas-
cular treatment.45 Paraplegia from spinal artery occlusion
occurred in only 1 patient, which compares favorably with
the reported 7% to 36% in patients who underwent surgery,
and was in accord with previous experience of 1.7% with
percutaneous stent-graft placement covering the entry tear
in the descending aorta.17,18,26,32,39,41 The 1-year cumu-
lative survival rate in this group was 90.2%, which compares
favorably with a surgically treated group, in whom the
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 4 Leurs et al 67712-month mortality rate was 33%.46 That in the current
aortic dissection group no aortic expansion was observed
may be due to the short follow-up time of only 1 year.
Endograft repair of false anastomotic aneurysm is usu-
ally a straightforward procedure, with placement of a single
stent graft and with a high technical success rate. Our
findings confirm the conclusion of a recent study that
stent-graft repair of false anastomotic aneurysm may be
preferable to surgical treatment.38 Rupture of thoracic
aorta from trauma is associated with a mortality rate as high
as 90%, because most patients die at the site of the accident.
Of patients who reach the hospital alive, 15% die before the
operation.47 Surgical treatment of a traumatic thoracic
rupture has a 30-day mortality rate of 15% to 30%, and a risk
for paraplegia of 2% to 20%.48-52 In the present series,
comparable with other reports,52 endovascular treat-
ment was associated with an early mortality rate of 6%,
which is considerably lower than the above indicated
rates with surgery. Because of the complexity of the
clinical situation in these patients, who often have mul-
tiple injuries, the timing of open surgical repair has long
been controversial.9,45 Unless a life-threatening hemo-
thorax exists, deliberately delayed surgical repair has
been mostly reported. The use of stent-graft treatment
has proved effective, and this approach is considered by
some as the first choice in management in these often
severely ill patients.25,53 Greater feasibility of endovas-
cular repair in the acute phase of thoracic aneurysm may
be an additional advantage over open surgery.54 In the
present series, comparable with other reports, endovas-
cular treatment demonstrated a considerably lower early
mortality rate (6%) compared with the above indicated
rates with surgery.
There are several weaknesses of this review. First,
registries in general consist of unaudited data, which may
result in underreporting of complications. However,
data collections in which the center is anonymous, such
as national or regional reviews, as a rule report higher
rates of postoperative deaths and complications than
institutional reports do.55 This makes it difficult to make
any assumption if, and to what extent, underreporting of
complications was the case. Second, the present report
was a compilation of the data of 2 separate and indepen-
dent registries. Although the main items corresponded
well, the case record forms used for data collection were
not completely congruent, and for assessment of some of
the questions only the data from 1 of the registries were
used. Finally, voluntary registries must be concise, be-
cause lengthy questionnaires may result in poor compli-
ance of data reporting. This has caused some lack of
information. For example, no differentiation was made
between different types of side branch occlusions at
presentation or different additional procedures (surgery
for access or side branch revascularization).
In conclusion, patients selected for endovascular repair
of diseases of the thoracic aorta had a considerable preva-
lence of preexisting comorbidity.Considering the number of patients unfit for open
surgery and the incidence of emergency procedures, the
overall 30-day and 1-year related outcomes in different
diseases were encouraging. Patients with dissections had
better outcomes than did those with degenerative aneu-
rysms. However, long-term efficacy of endovascular treat-
ment of TAAs and dissections remains to be demonstrated,
and lifelong surveillance remains necessary.
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Richard P. Cambria, MD, Boston, Mass
Stent-graft repair of thoracic aortic pathology has proceeded
at a frustrating pace on the North American side of the Atlantic.
The engineering, regulatory, and commercial interest issues re-
sponsible for this slow (compared with abdominal aortic aneu-
rysm) development have been the subject of considerable discus-
sion among the involved parties. At the present time, except for a
very few centers holding physician-sponsored Investigational De-
vice Exemptions, this technology is only available in the United
States in the form of 3 Phase II clinical trials, which are currently
restricted to treatment of degenerative thoracic aneurysms (DTA)
in candidates for open surgery. Furthermore, given the “morbidity
quotient” of conventional surgery for thoracic aortic (TA) pathol-
ogy, the clinical need for stent-graft repair in this area is both
obvious and pressing. The good news is that the latter is now
recognized by all parties involved and, with the imminent publica-
tion of the first US pivitol trial,1 there likely will be a commercially
available graft in the United States within a year.
The present Eurostar/United Kingdom registry report is cer-
tainly the largest compendium of patients treated with thoracic
aortic stent grafts. Readers of the Journal of Vascular Surgery are
accustomed to valuable clinical reports from the Eurostar registry,
and the present study will certainly serve (at least temporarily) as a
benchmark for periprocedural results achievable with TA stent
grafts. Procedural mortality was in line with the available literature,
particularly since many patients treated with TA stent grafts are in
genuinely desperate clinical circumstances. Emergency treatment
was required in half the dissection patients and in 25% of those with
DTA. The authors’ results with respect to central nervous system
complications are admirable. Stroke has been a vexing problem in
this arena, and I concur with their sanguine discussion concerning
the low—but not zero—risk of spinal cord ischemia.Limitations of this study are many and a function of the registry
format. This report is a cataloguing of procedures performed and,
accordingly, cannot address the important issues of patient clinical and
anatomic selection criteria. We know little or nothing of the indica-
tions for treatment, relative experience and expertise with open sur-
gery at the 62 contributing institutions, nor even the vigor of these
data. Fewer than 50% of patients had 1-year follow-up data available.
According to the data that were available, a disturbing 15% of DTA
patients experienced aneurysm expansion (although not defined)
despite low rates of endoleak and a zero graft-migration rate! Al-
though aneurysm-related death was rare, these data are in need of
clarification as more follow-up data become available.
As for the different pathologies treated, in the TA the spec-
trum is wide, from focal lesions (eg, traumatic tear, anastomotic
false aneurysm, penetrating ulcer) for which TA stent-graft repair
seems ideal, to complex clinical/anatomic circumstances (eg, Type
III B dissections) wherein definitive data can be generated only by
well-designed clinical trials. The authors record treatment of 50
cases of traumatic aortic tear with excellent overall results. Given
the incidence of this injury, this is a large number of cases, and
readers of JVS will soon be availed of other reports detailing similar
results with stent-graft repair of traumatic aortic tear. Despite the
general need of US endovascular surgeons to apply abdominal
aortic “cuffs” in an off-label application to repair traumatic tears, it
seems evident that the TA stent graft will soon be the treatment of
choice for this lesion. Such can hardly be considered the case in the
complexities of type B aortic dissection. Although the authors
treated some 130 cases, the indications for treatment and the
clinical circumstances thereof are vague and debatable, and the
desired detail in this regard is likely not retrievable from the registry
format. In type B dissection, stent-graft repair at the aortic entry
